| abstract |
The present invention provides a TGR5 receptornagonist comprising a fused ring compound represented bynthe formulan nwherein ring A is an optionally substituted aromaticnring; and ring B' is a 5- to 8-membered ring having onenor more substituents or a salt thereof or a prodrugnthereof, which is useful for the treatment of variousndiseases. |